The two products will be used in Opus Genetics’ research into inherited retinal disease, specifically bestrophin-1 and rhodopsin-mediated autosomal dominant retinitis pigmentosa, according to a Dec. 28 news release.
In exchange for the two products, Iveric Bio received $500,000 and “high single-digit percentage ownership of Opus,” according to the release. The company is also eligible for development and regulatory milestone payments, sales milestone payments, and a low single-digit earnout on net sales of the products. Iveric will retain certain rights with respect to the potential future commercialization of gene therapy products for BEST1 and/or RHO -adRP.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
